194 related articles for article (PubMed ID: 34769075)
1. Deciphering Evolutionary Dynamics and Lineage Plasticity in Aggressive Prostate Cancer.
Kyprianou N; Lucien F
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769075
[TBL] [Abstract][Full Text] [Related]
2. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Hofer MD
Fundam Clin Pharmacol; 2018 Oct; 32(5):547. PubMed ID: 30209857
[No Abstract] [Full Text] [Related]
3. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
4. Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy.
Pouliot F; Rouleau M; Neveu B; Toren P; Morin F; Vélot L; Ding K; Caron P; Lacombe L; Lévesque É; Klotz L; Guillemette C
J Urol; 2020 May; 203(5):940-948. PubMed ID: 31845837
[TBL] [Abstract][Full Text] [Related]
5. Management of hormone-sensitive metastatic prostate cancer.
Agarwal N; Hussain M
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1221-41, viii. PubMed ID: 24188260
[TBL] [Abstract][Full Text] [Related]
6. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
7. [Molecular genetic mechanisms of drug resistance in prostate cancer].
Krasnov GS; Dmitriev AA; Sadritdinova AF; Volchenko NN; Slavnova EN; Danilova TV; Snezhkina AV; Melnikova NV; Fedorova MS; Lakunina VA; Belova AA; Nyushko KM; Alekseev BY; Kaprin AD; Kudryavtseva AV
Mol Biol (Mosk); 2015; 49(5):716-27. PubMed ID: 26510590
[TBL] [Abstract][Full Text] [Related]
8. [Hormone dependency of prostate cancer].
Suzuki H; Ito H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():59-64. PubMed ID: 12599546
[No Abstract] [Full Text] [Related]
9. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
10. Androgen action and metabolism in prostate cancer.
Green SM; Mostaghel EA; Nelson PS
Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
[TBL] [Abstract][Full Text] [Related]
11. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
12. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
13. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
[TBL] [Abstract][Full Text] [Related]
14. Androgens in prostate cancer: A tale that never ends.
Hou Z; Huang S; Li Z
Cancer Lett; 2021 Sep; 516():1-12. PubMed ID: 34052327
[TBL] [Abstract][Full Text] [Related]
15. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
Ge R; Xu X; Xu P; Li L; Li Z; Bian J
Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
[TBL] [Abstract][Full Text] [Related]
16. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
17. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
18. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
19. Molecular aspects of hormone-independent prostate cancer.
Schalken JA
BJU Int; 2007 Jul; 100 Suppl 2():52-5. PubMed ID: 17594361
[No Abstract] [Full Text] [Related]
20. [The mechanism and predictive factors of hormone-independent recurrence of prostate cancer].
Tomita K; Kitamura T
Nihon Rinsho; 2002 Dec; 60 Suppl 11():70-5. PubMed ID: 12599548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
